The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:522-524 February 1, 2007 Number 5
NextNext

Effect of Ramipril on the Incidence of Diabetes

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by The DREAM Trial Investigators
-PubMed Citation
To the Editor: The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial investigators (Oct. 12 issue)1 report that there was an increase in the incidence of regression to normoglycemia (a secondary outcome) of 16% among patients receiving ramipril as compared with those receiving placebo but that there was no effect on the incidence of diabetes or death. The authors appear to have overlooked the significant reduction in mean diastolic blood pressure in the ramipril group, as compared with the reduction in the placebo group, at 2 months (4.3 mm Hg vs. 1.6 mm Hg). We wonder whether the . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.